FOR IMMEDIATE RELEASE
CONTACT: Alzheimer’s Association public relations department, 312.335.4078, media@alz.org

ALZHEIMER’S ASSOCIATION® MOURNS THE DEATH OF RESEARCHER, ALLEN ROSES, M.D.

CHICAGO, October 3, 2016 -- The Alzheimer's Association is saddened to learn of the death of pioneering researcher Allen Roses, M.D. Roses was a visionary and innovator in the fields of neurology, genetics, and drug development. His work significantly advanced our knowledge and understanding of Alzheimer’s disease.

The Alzheimer’s Association extends sincere condolences to Roses’ family, friends and colleagues.

Roses was keenly interested in uncovering the genetic and metabolic causes of Alzheimer’s disease, and their connections to age of onset of dementia symptoms. He led the team that in 1992 identified apolipoprotein E4 [APOE4] as a major susceptibility gene in late-onset Alzheimer’s disease. In 2009, Roses and colleagues linked the TOMM40 gene to risk for, and age of onset of, Alzheimer’s.

Moving between academia and industry, Roses formed one his several companies to test both a means of predicting cognitive decline in older adults and the ability of a repurposed diabetes drug to delay the onset of mild cognitive impairment due to Alzheimer’s in a global prevention trial called the TOMMORROW Study, which remains ongoing.

Roses was member of the Alzheimer’s Association Board of Directors from 1991-1999, and served on the Association’s Medical & Scientific Advisory Board.

Alzheimer's Association®
The Alzheimer's Association is the leading voluntary health organization in Alzheimer's care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. For more information, visit alz.org.

# # #